Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01637922 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01637922 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 34 participants.
The verdict
NCT01637922, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Otherwise healthy subjects who are currently bein maintained on either methadone or buprenorphine/naloxone for opioid maintenance therapy who have been on a stable dose for at least 30 days will be administered BI 201335 daily to determine if a drug interaction occurs between BI 201335 and either methadone or buprenorphine/naloxone.
Interventions
- DRUG BI 201335
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01637922
The ClinicalTrials.gov registry entry for NCT01637922 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 201335 is the first listed.
NCT01637922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01637922 about?
NCT01637922 is a clinical study titled "Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone". Otherwise healthy subjects who are currently bein maintained on either methadone or buprenorphine/naloxone for opioid maintenance therapy who have been on a stable dose for at least 30 days will be administered BI 201335 daily to determine if a drug interaction occurs between BI 201335 and either me...
What is the current status of trial NCT01637922?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-08. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01637922?
The interventions under investigation include: BI 201335 (DRUG).
Who is sponsoring clinical trial NCT01637922?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.